These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30372691)

  • 41. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.
    Cristiano G; Nanni J; Sartor C; Parisi S; Marconi G; Barbato F; Arpinati M; Bonifazi F; Curti A; Cavo M; Paolini S; Papayannidis C
    Acta Haematol; 2021; 144(6):688-692. PubMed ID: 34130278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China.
    Gao L; Zhang C; Gao L; Liu Y; Su Y; Wang S; Li B; Yang T; Yuan Z; Zhang X
    J Hematol Oncol; 2015 Jul; 8():90. PubMed ID: 26208715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Abou Dalle I; Jabbour E; Short NJ; Ravandi F
    Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
    Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ribera JM; García-Calduch O; Ribera J; Montesinos P; Cano-Ferri I; Martínez P; Esteve J; Esteban D; García-Fortes M; Alonso N; González-Campos J; Bermúdez A; Torrent A; Genescà E; Mercadal S; Martínez-Lopez J; García-Sanz R
    Blood Adv; 2022 Sep; 6(18):5395-5402. PubMed ID: 35675590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Nanno S; Matsumoto K; Nakamae M; Okamura H; Nishimoto M; Hirose A; Koh H; Nakashima Y; Nakane T; Morita K; Hino M; Nakamae H
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):813-819.e1. PubMed ID: 32800519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.
    Sasaki H; Mitani S; Kusumoto S; Marumo Y; Asano A; Yoshida T; Narita T; Ito A; Yano H; Ri M; Ishida T; Komatsu H; Iida S
    Int J Hematol; 2019 Jul; 110(1):119-123. PubMed ID: 30879266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
    Malagola M; Papayannidis C; Baccarani M
    Ann Hematol; 2016 Apr; 95(5):681-93. PubMed ID: 26891878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
    IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Multicentre, Randomized Trial in Adults with de novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia to Assess the Efficacy of Ponatinib versus Imatinib in Combination with Low-Intensity Chemotherapy, to Compare End of Therapy with Indication for Stem Cell Transplantation versus Tyrosine Kinase Inhibitor, Blinatumomab, and Chemotherapy in Optimal Responders, and to Evaluate Blinatumomab in Suboptimal Responders (GMALL-EVOLVE).
    Lang F; Pfeifer H; Brüggemann M; Hermann E; Serve H; Goekbuget N
    Oncol Res Treat; 2024; 47(9):430-433. PubMed ID: 38754400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].
    Yu X; Li C; Wu X; Ye L; Liu H; Ma C; Ma J; Gu C; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):129-33. PubMed ID: 24606654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
    Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    Yurkiewicz IR; Muffly L; Liedtke M
    Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups.
    Mo XD; Xu LP; Zhang XH; Liu DH; Wang Y; Chen H; Yan CH; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Int J Cancer; 2015 Apr; 136(7):1697-707. PubMed ID: 25138425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.